^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Non Small Cell Lung Cancer
    Drug:RMC-9805 (KRAS G12D inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

    Excerpt:
    ...- Pathologically documented, locally advanced or metastatic solid tumor malignancy with KRASG12D-mutations identified through deoxyribonucleic acid (DNA) sequencing or polymerase chain reaction (PCR) test...
    Trial ID:
    NCT06040541
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    526 / 26 - RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

    Published date:
    03/15/2023
    Excerpt:
    In a mouse clinical trial with KRAS G12D xenograft tumor models, RMC-9805 administered orally as a single agent was well tolerated and induced objective responses in 7 of 9 PDAC PDX and CDX models and 6 of 9 NSCLC PDX models, as assessed by mRECIST.